BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31850201)

  • 1.
    Wang ZY; Ding XQ; Zhu H; Wang RX; Pan XR; Tong JH
    Front Oncol; 2019; 9():1295. PubMed ID: 31850201
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer.
    Motobayashi H; Kitahata Y; Okada KI; Miyazawa M; Ueno M; Hayami S; Miyamoto A; Shimizu A; Sato M; Yoshimura T; Nakamura Y; Takemoto N; Nakai T; Hyo T; Matsumoto K; Yamaue H; Kawai M
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):35. PubMed ID: 38277079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasensitive plasma ctDNA
    Chen I; Raymond VM; Geis JA; Collisson EA; Jensen BV; Hermann KL; Erlander MG; Tempero M; Johansen JS
    Oncotarget; 2017 Nov; 8(58):97769-97786. PubMed ID: 29228650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.
    Guan S; Deng G; Sun J; Han Q; Lv Y; Xue T; Ding L; Yang T; Qian N; Dai G
    Front Oncol; 2022; 12():926260. PubMed ID: 36081557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy from Bile-Circulating Tumor DNA in Patients with Biliary Tract Cancer.
    Han JY; Ahn KS; Kim TS; Kim YH; Cho KB; Shin DW; Baek WK; Suh SI; Jang BC; Kang KJ
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer.
    Tjensvoll K; Lapin M; Buhl T; Oltedal S; Steen-Ottosen Berry K; Gilje B; Søreide JA; Javle M; Nordgård O; Smaaland R
    Mol Oncol; 2016 Apr; 10(4):635-43. PubMed ID: 26725968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct circulating tumor DNA detection from unpurified plasma using a digital PCR platform.
    Sefrioui D; Beaussire L; Perdrix A; Clatot F; Michel P; Frebourg T; Di Fiore F; Sarafan-Vasseur N
    Clin Biochem; 2017 Nov; 50(16-17):963-966. PubMed ID: 28645720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer.
    Hayashi T; Yoshida Y; Yamada T; Tanaka K; Shimaoka H; Kajitani R; Munechika T; Nagano H; Matsumoto Y; Komono A; Sakamoto R; Aisu N; Yoshimatsu G; Yoshimura F; Hasegawa S
    Cancer Med; 2022 Aug; 11(16):3126-3135. PubMed ID: 35312176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma.
    Wang J; Huang A; Wang YP; Yin Y; Fu PY; Zhang X; Zhou J
    Ann Transl Med; 2020 Mar; 8(5):237. PubMed ID: 32309384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    Cho MS; Park CH; Lee S; Park HS
    PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review.
    Huerta M; Roselló S; Sabater L; Ferrer A; Tarazona N; Roda D; Gambardella V; Alfaro-Cervelló C; Garcés-Albir M; Cervantes A; Ibarrola-Villava M
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33673558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy.
    Kitahata Y; Kawai M; Hirono S; Okada KI; Miyazawa M; Motobayashi H; Ueno M; Hayami S; Miyamoto A; Yamaue H
    Ann Surg Oncol; 2022 Mar; 29(3):1596-1605. PubMed ID: 34724126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer.
    Lin M; Alnaggar M; Liang S; Chen J; Xu K; Dong S; Du D; Niu L
    Cell Physiol Biochem; 2018; 47(4):1556-1564. PubMed ID: 29940591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.
    Freidin MB; Freydina DV; Leung M; Montero Fernandez A; Nicholson AG; Lim E
    Clin Chem; 2015 Oct; 61(10):1299-304. PubMed ID: 26272233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.